cnb791 ht logo promo |

Introducing the new PhysioMimix Single-Organ Higher Throughput System

Learn more
CN Bio logo CN Bio logo CN Bio logo CN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • Immune-mediated DILI – Predicting the unpredictable!

      • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing

      • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System  

      View all news

      Upcoming Events

      • SLAS Europe 2023

      • SOT 2023

      • WORD 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      • Doctoral Researcher (Horizon Marie Curie Doctoral Network Project)

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Chat live with an expert

CN Bio and iiCON announce COVID-19 research collaboration

November 9, 2021 by CN Bio

  • Partnership focused on validation of novel Organ-on-a-Chip infection models
  • Human-relevant single and multi-organ SARS-CoV-2 infected models developed using Innovate UK grant
  • 3D lung cell culture technology to support more efficient and accurate COVID-19 therapeutic discovery and development

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced a research collaboration with the Infection Innovation Consortium (iiCON), a global collaborative infectious disease R&D programme, to validate the next generation of COVID-19 research tools.

iiCON’s £174 million programme brings together industry, academia, and clinicians to accelerate the discovery, development and deployment of new treatments and products – saving and improving millions of lives through collaborative innovation. Led by the Liverpool School of Tropical Medicine (LSTM), its partner members are Unilever, Evotec, Liverpool University Hospitals Foundation Trust, University of Liverpool, and Infex Therapeutics.

Under the terms of the agreement, iiCON lead partner, LSTM, a world-leading institute for infectious disease research, will independently validate CN Bio’s novel lung and lung-liver models, designed to advance novel SARS-CoV-2 drug discovery and development.

Expanding on the project with Innovate UK, within nine months, CN Bio’s perfused lung models are to be transferred to LSTM for validation, to demonstrate the ability of the PhysioMimix systems to support the full viral life cycle of SARS-CoV-2 and facilitate testing with anti-viral compounds. LSTM will validate the systems’ use in high containment laboratories (CL3) for studies with infectious viral materials and validate the system’s potential to identify PK/PD indices and PD Targets for the development of safe and efficacious dosing regimens of new antiviral therapeutics.

Following this initial evaluation, it is intended that iiCON will have access to the PhysioMimix technology and its associated 3D tissue models for a variety of translational infectious disease projects. A successful outcome from the collaboration will support researchers globally by providing advanced insights to SARS-CoV-2 infections in humans and enable CN Bio to expand its portfolio of OOC models to address a broader and more diverse range of therapeutic areas.


Dr Tomasz Kostrzewski, Director of Biology, CN Bio, said:

“iiCON’s commitment to collaborative innovation has enabled our pioneering partnership with consortium lead, LSTM. This collaboration will provide access to the institute’s world–leading expertise in infectious disease research, in addition to the consortium’s outstanding industry links.

“As a result of this collaboration, it is our joint intention that the data generated will be published, providing us with proof that supports the adoption of PhysioMimix microphysiological systems into industry, where they can be used as translational tools to accelerate understanding of SARS-CoV-2 infection and consequently, accelerate the development of new therapeutic options.”


Professor Giancarlo Biagini, iiCON Platform Lead, Head of the Department of Tropical Disease Biology at LSTM, and UKRI Innovation Scholar, said:

“Facilitating the industry academic interface to drive forward transformative technologies and fast-track innovative health solutions to our most pressing global infectious disease challenges is at the heart of iiCON’s purpose.

“As part of the consortium, LSTM is delighted to be entering into this key agreement with CN Bio. By leveraging emerging organ-on-a-chip technology, we aim to develop pre-clinical platforms that accelerate translational research of new therapeutics to manage and treat major human infections, including emerging and high consequence infectious diseases such SARS-COV-2.”

For more information about CN Bio’s Organ-on-a-Chip technology, visit:

https://cn-bio.com/organ-on-chip/

  1. Press release: CN Bio awarded Innovate UK grant to develop single and multi-organ models for COVID-19 research (1st March, 2021)
  2. Jain U. Effect of COVID-19 on the Organs. Cureus. 2020;12(8):e9540. Published 2020 Aug 3. doi:10.7759/cureus.9540

Category iconPress releases

Primary Sidebar

Other recent news

  • Immune-mediated DILI – Predicting the unpredictable! March 16, 2023
  • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing March 14, 2023
  • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System   February 27, 2023
  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • Immune-mediated DILI – Predicting the unpredictable! March 16, 2023
  • CN Bio appoints Deepak Singh as Vice President of Sales and Marketing March 14, 2023
  • CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System   February 27, 2023

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SOT 2023 March 19-23, 2023

WORD 2023 March 22, 2022